Roche Holding AG Cash Flow from Operating Activities 2012-2025 | RHHBY
Roche Holding AG annual/quarterly cash flow from operating activities history and growth rate from 2012 to 2025. Cash flow from operating activities can be defined as a company's cash flows from operations.
- Roche Holding AG cash flow from operating activities for the quarter ending December 31, 2025 was $22.754B, a 158.99% increase year-over-year.
- Roche Holding AG cash flow from operating activities for the twelve months ending December 31, 2025 was $72.258B, a 18.69% increase year-over-year.
- Roche Holding AG annual cash flow from operating activities for 2025 was $22.754B, a 0.31% decline from 2024.
- Roche Holding AG annual cash flow from operating activities for 2024 was $22.825B, a 27.31% increase from 2023.
- Roche Holding AG annual cash flow from operating activities for 2023 was $17.928B, a 7.09% decline from 2022.
|
Roche Holding AG Annual Cash Flow Ops (Millions of US $) |
|
|---|---|
| 2025 | $22,754 |
| 2024 | $22,825 |
| 2023 | $17,928 |
| 2022 | $19,297 |
| 2021 | $22,950 |
| 2020 | $19,803 |
| 2019 | $22,531 |
| 2018 | $20,427 |
| 2017 | $18,318 |
| 2016 | $15,231 |
| 2015 | $15,872 |
| 2014 | $17,432 |
| 2013 | $17,026 |
| 2012 | $16,012 |
| 2011 | $14,668 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $318.782B | $76.450B |
| Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |